Ranbaxy loses 180-day exclusivity on generic version of AstraZeneca's Nexium

January 27, 2015 8:16 AM

13 0

The American drug regulator has revoked Ranbaxy Laboratories' 180-day exclusivity for selling a low cost version of AstraZeneca's blockbuster heartburn drug Nexium, as per a stock market disclosure.

“We have received a communication from USFDA that they are determined that Ranbaxy has forfeited its 180-day exclusivity for esomeprazole magnesium delayed release capsule 20 mg and 40 mg,” it stated.

Also read: Stock market value of Netflix eclipses Disney for first time

Read more

To category page